MGEN - miRagen Therapeutics changes name to Viridian; announces leadership changes
miRagen Therapeutics (MGEN) announced its name change to Viridian Therapeutics and ticker symbol 'VRDN'; to commence trading tomorrow.The company appointed Jonathan Violin, Ph.D., M.B.A. as President and CEO succeeding Lee Rauch who will remain as strategic advisor to the company; Dr. Violin earlier served as president & COO.Also, internationally recognized neuro-ophthalmologist, Barrett Katz M.D., M.B.A., is appointed as Chief Medical Officer; most recently he served at BridgeBio Pharma where he developed therapeutics to treat orphan eye diseases.In 2H21, the company expects to file Investigational New Drug applications for both VRDN-001 and VRDN-002.Shares traded 2.21% down premarket.
For further details see:
miRagen Therapeutics changes name to Viridian; announces leadership changes